乳腺癌扩增基因1与雄激素受体表达与乳腺癌他莫昔芬耐药的关系  

The relationship between the expression of amplified in breast cancer 1、androgen receptor and tamoxifen resistance in breast cancer

作　　者：刘宁[1] 孟庆祥 王广舜[3] Liu Ning;Meng Qingxiang;Wang Guangshun(Department of Pathology,Tianjin Baodi Hospital,Tianjin 301800,China;Department of Anesthesiology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research for Cancer,Tianjin 300060,China;Department of Oncology,Tianjin Baodi Hospital,Tianjin 301800,China)

机构地区：[1]天津市宝坻区人民医院病理科,天津301800 [2]天津医科大学肿瘤医院麻醉科国家恶性肿瘤临床医学研究中心,天津300060 [3]天津市宝坻区人民医院肿瘤科,天津301800

出　　处：《中华医学杂志》2023年第20期1553-1559,共7页National Medical Journal of China

摘　　要：目的探讨乳腺癌扩增基因1(AIB1)和雄激素受体(AR)表达在雌激素受体(ER)阳性乳腺癌他莫昔芬(TAM)疗效中的意义。方法本研究为回顾性病例研究,收集天津医科大学肿瘤医院2008年6月至2013年7月188例病理诊断ER阳性乳腺癌组织,均为女性,年龄25~87岁,采用免疫组化方法(IHC)检测AIB1及AR在188例乳腺癌患者组织中的表达情况,分析二者与TAM疗效及耐药的关系,并通过基因表达研究交互式分析(GEPIA)数据库验证本研究的结果。结果TAM治疗的总有效率为80.3%。TAM治疗有效率在AR阳性组、阴性组中分别为79.6%(109/137)、82.4%(42/51),差异无统计学意义(P=0.669)。TAM治疗有效率在AIB1高表达组为68.4%(67/98),AIB1低表达组为93.3%(84/90),差异有统计学意义(P<0.001),显示AIB1高表达患者容易对TAM产生耐药。TAM在AR阴性AIB1低表达、AR阴性AIB1高表达,AR阳性AIB1低表达以及AR阳性AIB1高表达四组中的治疗有效率分别为89.7%(26/29)、71.4%(15/21)、96.7%(59/61)、66.2%(51/77),低表达组与高表达组比较差异有统计学意义(P<0.001)。结论AIB1表达与乳腺癌TAM疗效具有相关性,其高表达易产生TAM耐药,而AR阳性且AIB1高表达更易引起TAM耐药,并且AIB1可作为乳腺癌TAM治疗疗效的影响因素。Objective To discuss the value of amplified in breast cancer 1(AIB1)and androgen receptor(AR)for the resistance of adjuvant tamoxifen in estradiol receptor(ER)positive breast cancer.Methods A total of 188 cases with breast cancer after receiving tamoxifen treatment in the Tianjin Medical University Cancer Institute and Hospital from June 2008 to July 2013 were enrolled in this study.Using immunohistochemical SP method to detect AIB1and AR expression in breast cancer tissue,analyzing the relationship of AIB1 and AR expression and the effect of tamoxifen.And verify the results of the experiment through the GEPIA database.Results The response of tamoxifen was 80.3%.The response rate in AR positive group and AR negative group was 79.6%and 82.4%,with no significant difference(P=0.669).The response rate in AIB1 High expression group and AIB1 Low expression group was 68.4%and 93.3%,respectively,with a significant difference(P<0.001).The response rate in AR negative and AIB1 Low expression group,AR negative and AIB1 High expression group,AR positive and AIB1 Low expression group,AR positive and AIB1High expression group was 89.7%,71.4%,96.7%,66.2%respectively,with a significant difference(P<0.001).Conclusions The expression level of AIB1 is correlated with the therapeutic effect of tamoxifen in breast cancer.Its high expression can cause tamoxifen resistance,while AR positive and High expression of AIB1 are more likely to cause tamoxifen resistance,and AIB1 can be used as an independent influencing factor for breast cancer tamoxifentreatment.

关 键 词：乳腺肿瘤 乳腺癌扩增基因1 雄激素受体 他莫昔芬耐药 

分 类 号：R737.9[医药卫生—肿瘤]